

Art Unit: \*\*\*

12/27/05  
CLMPTO  
dw

## Claims 1-26 (Canceled)

27. (currently amended) A method for treating human subjects with blood clotting disorders, comprising:

administering a pharmaceutical composition to the human subjects,

wherein the pharmaceutical composition comprises a peptide having a total length of from 3 to 10 amino acids in total length,

wherein said peptide comprises a sequence ~~of between 3 and 10 amino acids,~~ which is identical to a sequence of from 3 to 10 consecutive amino acids found within amino acids 32216 to 33125 or 35246 to 35650 of the human blood clotting factor Va (SEQ ID NO: 1), wherein SEQ ID No: 1 represents amino acids 307 to 356 of the human blood clotting factor Va, and

wherein the peptide exhibits an IC<sub>50</sub> of between 50 nM to 500 ~~μ~~M for inhibition of prothrombinase.

28. (currently amended) The method of claim 27 wherein the peptide comprises at least 5 amino acids which are identical to a sequence of consecutive amino acids found within amino acids ~~32216 to 33125 or 35246 to 35650 of the human blood clotting factor Va (SEQ ID NO: 1), wherein SEQ ID No: 1 represents amino acids 307 to 356 of the human blood clotting factor Va.~~

Art Unit: \*\*\*

29. (currently amended) The method of claim 27 wherein the peptide comprises at least 7 amino acids which are identical to a sequence of consecutive amino acids found within amino acids ~~32216 to 33125 of the human blood clotting factor Va~~ (SEQ ID NO: 1), wherein SEQ ID No: 1 represents amino acids 307 to 356 of the human blood clotting factor Va.

30. (currently amended) The method of claim 27 wherein the peptide comprises at least 10 amino acids which are identical to a sequence of consecutive amino acids found within amino acids ~~32216 to 33125 of the human blood clotting factor Va~~ (SEQ ID NO: 1), wherein SEQ ID No: 1 represents amino acids 307 to 356 of the human blood clotting factor Va.

31. (currently amended) The method of claim 27, wherein the sequence of the peptide is selected from the group consisting of SEQ ID NO: 6 and SEQ ID NO: 12.

32. (previously presented) The method of claim 27, wherein at least one amino acid within said peptide is a non-naturally occurring amino acid.

33. (previously presented) The method of claim 27, wherein at least one amino acid within said peptide is a D-amino acid.

34. (currently amended) The method of claim 27, wherein at least two amino acids in said sequence are joined by non-hydrolyzable peptide bonds.

35. (currently amended) The peptide of claim 27, wherein said peptide is a cyclized peptide.